Search results
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 18 hours agoAnd like Pfizer, BMS sports a robust clinical pipeline, highlighted by potential future stars like...
This Is What Whales Are Betting On Bristol-Myers Squibb - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 16 hours agoA key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence ...
FDA grants approval for Bristol Myers Squibb’s Augtyro for solid tumours
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers...
Quinn Myers
WBEZ 91.5 Chicago· 2 days agoQuinn Myers
Fort Myers man accused of trafficking 20 grams of fentanyl and more street-level narcotics
NBC 2 Fort Myers· 5 days agoFort Myers SWAT and officers seized street-level narcotics after an undercover controlled buy...
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
Zacks via Yahoo Finance· 5 days agoThe FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric...
Gateway - Quartz
Quartz· 22 hours agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar drug that dominates a market, brings in hordes of customers, and deposits ...
Baysient® Launches Therapeutic Drug Monitoring Software for Oncology Biologics
Benzinga· 23 hours agoBaysient®, a leading provider of therapeutic drug monitoring (TDM) software, today announced the launch of TuMinimize™, a web-based nomogram/algorithm designed to optimize ...
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
Morningstar· 5 days agoBy Denny Jacob Bristol Myers Squibb disclosed that the U.S. Food and Drug Administration granted accelerated approval of Augtyro. The biopharmaceutical product developer said ...
M&A Is Back. 4 Stocks That Could Be Targets.
Barrons.com· 2 hours agoMergers are back—and that means opportunity for small-cap investors. The return of M&A has been helped along by a number of factors, including a...